Investor Presentaiton
Indication
Current
trials
CLARITY
2014 MEIE
Product
Three core product areas in clinical trials
Clarity has potential to address multiple oncology indications with unmet needs through a range of products and
their applications. These include large indications, such as prostate and breast cancers, as well as small and
orphan indications, such as neuroendocrine tumours (NETs) and neuroblastoma, an aggressive childhood cancer.
SAR-bisPSMA
Cancers that express Prostate
Specific Membrane Antigen
(PSMA)
SAR-Bombesin
SARTATE™M
Cancers that express Gastrin Releasing Peptide
Cancers that express
Somatostatin Receptor 2
receptor (GRPr)
(SSTR2)
Prostate Cancer
Breast
Cancer
Neuro-
blastoma
NETS
Theranostic
Diagnostic
Theranostic
Diagnostic
Diagnostic
Theranostic Diagnostic
Each core product can be used as a diagnostic or as a therapy
Each product
targets a distinct
receptor present
on the surface of
cells of a range of
cancers
7View entire presentation